The ultra-sensitive SureSeq™ Myeloid MRD Plus NGS Panel leverages OGT’s expertise in hybrid capture to provide a flexible NGS workflow for the detection of ultra-low frequency measurable residual disease (MRD)-associated biomarkers in acute myeloid leukemia (AML).
Including longer, ultra-low frequency FLT3-ITDs over 300bp long, for the clearest picture of MRD status
As low as 0.01% VAF, including for key targets like NPM1
Maximize the efficiency of your MRD solution
Our complimentary NGS analysis software provides an out of the box bioinformatic pipeline
In a cohort of 16 AML clinical research samples with detected variants, OGT's SureSeq Myeloid MRD Panel:
By leveraging our expertise in hybrid capture technology and sequence identification analysis, the SureSeq Myeloid MRD Plus NGS Panel can detect large FLT3-ITDs, in excess of 300bp, so you don’t miss actionable insights.
Data generated using the SureSeq Myeloid MRD NGS Panel in combination with the OGT’s Universal NGS Workflow Solution V2 and OGT’s Interpret NGS Analysis Software highlights the detection of a 300 bp FLT3-ITD as well as 3 examples of FLT3-ITD detection in orthogonally validated research samples.
Total hands-on time: 3hr 40 mins
* Exon examples not yet available
Overall, we were very happy with the promising results we obtained using the SureSeq Myeloid MRD Panel which has led us to implement this panel for MRD analysis in our ongoing and planned clinical trials. In our hands this panel was able to detect all variants found by a comparator NGS panel, generating no false positive calls, and most importantly, several additional clinically relevant variants, including FLT3-ITDs, that had not been detected by the comparator were found.
Klaus H. Metzeler, MD
Professor of Translational Hematology, Dept. of Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig, Germany
Visit International site
Visit Canada site
